AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017
Oct 18, 2017
29864_dirs_2017-10-18_abfa0bc0-7c7c-4087-ae1b-8b824a897782.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-10-16
Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-16 | Common Stock | M | 1718 | $96.87 | Acquired | 116142 | Direct |
| 2017-10-16 | Common Stock | S | 300 | $153.42 | Disposed | 115842 | Direct |
| 2017-10-16 | Common Stock | S | 818 | $154.76 | Disposed | 115024 | Direct |
| 2017-10-16 | Common Stock | S | 300 | $155.92 | Disposed | 114724 | Direct |
| 2017-10-16 | Common Stock | S | 300 | $157.38 | Disposed | 114424 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-10-16 | Stock Option (Right to Buy) | $96.87 | M | 1718 | Disposed | 2024-07-14 | Common Stock (1718) | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
F2: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3: Open market sales reported on this line occurred at a weighted average price of $153.42 (range $153.11 to $153.58).
F4: Open market sales reported on this line occurred at a weighted average price of $154.76 (range $154.50 to $155.15).
F5: The option vests in 16 quarterly installments from 7/15/2014.